TrialCurveCirCe01: reconstructed Kaplan–Meier curves
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Br J Cancer. 2021 Jan 21;124(7):1207–13. doi: 10.1038/s41416-020-01227-3 |
|---|---|
| DOI | 10.1038/s41416-020-01227-3 |
| Registry | NCT01349842 |
| Phase | Phase 3 |
| Conditions | Breast Cancer Ductal Infiltrating Metastatic |
| Interventions | Blood sampling, Usual clinical and radiological criteria |
| Sponsor | Institut Curie |
| Enrolment | 265 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival
From figure panel a · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Arm A 4.0 months; Arm B 3.6 months. Survival at 6 months: Arm A 31%; Arm B 30%. Hazard ratio Arm A vs Arm B 0.91 (95% CI 0.61–1.36).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Arm A | 51 | 49 | 4.0 |
| Arm B | 50 | 49 | 3.6 |
- Arm A vs Arm B: reconstructed HR 0.91 (95% CI 0.61–1.36)
Landmark survival (reconstructed)
| Time | Arm A | Arm B |
|---|---|---|
| 6 mo | 31.4% | 30.0% |
| 12 mo | 13.1% | 10.0% |
| 18 mo | 4.4% | 6.0% |
Overall survival
From figure panel b · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Arm A 8.8 months; Arm B 11.2 months. Survival at 12 months: Arm A 43%; Arm B 44%. Hazard ratio Arm A vs Arm B 0.91 (95% CI 0.61–1.37).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Arm A | 51 | 48 | 8.8 |
| Arm B | 50 | 49 | 11.2 |
- Arm A vs Arm B: reconstructed HR 0.91 (95% CI 0.61–1.37)
Landmark survival (reconstructed)
| Time | Arm A | Arm B |
|---|---|---|
| 6 mo | 56.9% | 74.0% |
| 12 mo | 42.9% | 44.0% |
| 18 mo | 28.6% | 30.0% |
| 24 mo | 24.5% | 16.0% |
| 36 mo | 6.1% | 2.0% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/circe01-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/circe01-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Br J Cancer. 2021 Jan 21;124(7):1207–13. doi: 10.1038/s41416-020-01227-3 doi:10.1038/s41416-020-01227-3. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/circe01
Report a problem with these data
Related trials
- PANTHER: Breast cancer recurrence-free survival events (cumulative incidence)
- NK105 vs paclitaxel in metastatic breast cancer: Overall survival; Progression-free survival
- FURVA: Overall survival; Progression-free survival
- TROIKA (final analysis): Event free survival
- FAKTION: Overall survival; Progression-free survival
- ACE-Breast-02: Overall survival; Progression-free survival assessed by BICR; Progression-free survival as
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials